FDAnews
www.fdanews.com/articles/72171-adherex-initiates-phase-ii-trial-of-adh-1

Adherex Initiates Phase II Trial of ADH-1

May 11, 2005

Adherex Technologies has initiated a Phase II clinical trial of ADH-1 (Exherin) at the Ottawa Regional Cancer Centre in Ottawa, Ontario, Canada.

The study is designed to evaluate the antitumor activity and tolerability of repeated doses of ADH-1 on an every three-week schedule in patients whose tumors express the molecular target, N-cadherin. In addition to the Ottawa location, this open-label trial is expected to include up to two additional sites in Canada.

This trial, the first in the company's Phase II ADH-1 program, is expected to enroll up to 60 patients and will include eight different tumor types, including some more common cancers such as breast and lung as well as some rare cancers such as adrenocortical and esophageal. The trial size could be increased beyond 60 patients, depending on the level of antitumor activity noted. The company expects the trial to conclude in the second half of 2006.